ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1959

Multimorbidity in Patients with Sarcoidosis: A Population-Based Cohort Study

Patompong Ungprasert1, Eric L. Matteson2 and Cynthia S. Crowson3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Department of Medicine, Division of Rheumatology,Mayo Clinic, Rochester, MN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Co-morbidities, Epidemiologic methods, Population studies and sarcoidosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Multimorbidity in Patients with Sarcoidosis: A Population-Based Cohort Study

Background/Purpose:   Recent studies have suggested an increased risk of comorbidity in patients with sarcoidosis.  However, whether sarcoidosis is associated with increased incidence of multimorbidity is not known.

Methods: 345 patients (50% female; 90% Caucasian, 5% African-American; mean age 45.6 years) with incident sarcoidosis in 1976-2013 in a geographically well-defined population were identified from a comprehensive medical record linkage system.  Diagnosis of sarcoidosis was confirmed by individual medical record review which required diagnosis of sarcoidosis by physician supported by histopathology, compatible clinical presentation, and exclusion of other granulomatous diseases. A total of 345 sex and age-matched comparators (50% female; 95% Caucasian, 1% African-American; mean age 45.4 years) were also identified from the same underlying population. Cases and comparators were then reviewed for 18 common chronic comorbidities at index date and after index date.  Aalen-Johansen methods were used to estimate the cumulative incidence of multimorbidity (defined as presence or at least 2 chronic comorbidities) adjusted for the competing risk of death. Cox proportional hazards models with adjustment for age, sex, and calendar year were used to compare the rate of development of multimorbidity between cases and comparators.  

Results: At index date, 111 patients with sarcoidosis and 110 comparators without sarcoidosis had multimorbidity (p value 1.0).  The mean number of comorbidities was 1.2 in both groups. During a median follow-up of 12.9 years among patients with sarcoidosis and 15.6 years among comparators, 156 patients with sarcoidosis developed multimorbidity compared to 142 comparators, corresponding to an adjusted hazard ratio of 1.60 (95% confidence interval, 1.07 – 1.69).  The percentage of patients developing multimorbidity by years since sarcoidosis incidence/index date is shown in the figure.  Analysis by specific comorbidity revealed significantly increased incidence of congestive heart failure, coronary artery disease, arrhythmia, cerebrovascular accident, arthritis, asthma, depression, diabetes and osteoporotic fracture after the index date among patients with sarcoidosis. The most common combination of comorbidities was hypertension and hyperlipidemia, although these were not significantly increased in sarcoidosis relative to comparators.

Conclusion: This first ever population-based evaluation of multimorbidity in sarcoidosis revealed that patients have a significantly increased incidence of multimorbidity after the diagnosis of sarcoidosis.

Figure. Probability of developing 2,3,4, 5+ comorbidities according to years since sarcoidosis incidence/ index date for patients with sarcoidosis (S) and comparators (C).

 


Disclosure: P. Ungprasert, None; E. L. Matteson, None; C. S. Crowson, None.

To cite this abstract in AMA style:

Ungprasert P, Matteson EL, Crowson CS. Multimorbidity in Patients with Sarcoidosis: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/multimorbidity-in-patients-with-sarcoidosis-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multimorbidity-in-patients-with-sarcoidosis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology